Our center promotes drug discovery research based on the concept of One Medicine to radically improve the success rate of drug development for human and animals and cultivates a new academic field, Sharing Medicine.
Japan has contributed to development of pharmaceuticals that have revolutionized global medicine, such as statins, immune checkpoint inhibitors, and antiparasitic drugs in the past. However, in the aftermath of the global spread of COVID-19, Japan has fallen behind in the creation of vaccines and therapeutic drugs. The ensuant decline in research capabilities in the life science field casts a shadow over drug discovery research, making it problematic for the country to regain a leadership role in drug discovery research. While expediting preclinical and clinical research on drug discovery seeds has been emphasized, a radical change is needed to dramatically advance the success rate.
The perspective of researching human and animal diseases in tandem, One Medicine, can satisfy this need by developing drug discovery seeds based on structural biology, cell/regenerative medicine, and informatics by generating disease model animals based on comparative medicine and employing researchers in medicine, veterinary medicine, pharmacology, and engineering who collaborate across fields and facilities in Japan and overseas to develop promising drug discovery seeds. There is an urgent need to create a system that facilitates advanced selection of drug seeds and accelerates preclinical and clinical trials.
Our center promotes drug discovery research based on the concept of One Medicine to radically improve the success rate of drug development and cultivate a new academic field Sharing Medicine. Please consider joining us in the project.
Director Daisuke Yabe, MD, PhD